Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry

Cystic fibrosis (CF) is a lethal genetic disease caused by the loss or dysfunction of the CF transmembrane conductance regulator (CFTR) channel. F508del is the most prevalent mutation of the CFTR gene and encodes a protein defective in folding and processing. VX‐809 has been reported to facilitate the folding and trafficking of F508del‐CFTR and augment its channel function. The mechanism of action of VX‐809 has been poorly understood. In this study, we sought to answer a fundamental question underlying the mechanism of VX‐809: does it bind CFTR directly in order to exert its action? We synthesized two VX‐809 derivatives, ALK‐809 and SUL‐809, that possess an alkyne group and retain the rescue capacity of VX‐809. By using CuI‐catalyzed click chemistry, we provide evidence that the VX‐809 derivatives bind CFTR directly in vitro and in cells. Our findings will contribute to the elucidation of the mechanism of action of CFTR correctors and the design of more potent therapeutics to combat CF.

[1]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Genetic Analysis , 1989, Science.

[2]  Jason C. Young,et al.  Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane , 2010, Science.

[3]  J. Riordan,et al.  Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  S Grinstein,et al.  The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. , 1993, The Journal of biological chemistry.

[5]  R. Boucher.  Cystic fibrosis: a disease of vulnerability to airway surface dehydration. , 2007, Trends in molecular medicine.

[6]  S. Matalon,et al.  Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. , 2010, American journal of respiratory cell and molecular biology.

[7]  Philip J. Thomas,et al.  Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences , 2012, Cell.

[8]  J. Kappes,et al.  A young Hispanic with c.1646G>A mutation exhibits severe cystic fibrosis lung disease: is ivacaftor an option for therapy? , 2012, American journal of respiratory and critical care medicine.

[9]  R. Pettit.  Cystic Fibrosis Transmembrane Conductance Regulator–Modifying Medications: The Future of Cystic Fibrosis Treatment , 2012, The Annals of pharmacotherapy.

[10]  M. Gentzsch,et al.  The Cystic Fibrosis Transmembrane Conductance Regulator Impedes Proteolytic Stimulation of the Epithelial Na+ Channel*♦ , 2010, The Journal of Biological Chemistry.

[11]  James Rader,et al.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[12]  M. Amaral,et al.  Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. , 2007, Trends in pharmacological sciences.

[13]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[14]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[15]  R. Boucher,et al.  Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. , 2008, Current opinion in pharmacology.

[16]  Min Goo Lee,et al.  Rescue of ΔF508-CFTR Trafficking via a GRASP-Dependent Unconventional Secretion Pathway , 2011, Cell.

[17]  Hong Yu Ren,et al.  VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1 , 2013, Molecular biology of the cell.

[18]  M. Best,et al.  Click chemistry and bioorthogonal reactions: unprecedented selectivity in the labeling of biological molecules. , 2009, Biochemistry.

[19]  D. Clarke,et al.  Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule. , 2009, Biochemistry.

[20]  F. van Goor,et al.  Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[21]  Increasing the efficacy of bioorthogonal click reactions for bioconjugation: a comparative study. , 2011, Angewandte Chemie.

[22]  K. Arora,et al.  Compartmentalization of cyclic nucleotide signaling: a question of when, where, and why? , 2013, Pflügers Archiv - European Journal of Physiology.

[23]  A S Verkman,et al.  Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis. , 2012, Bioorganic & medicinal chemistry.

[24]  Jinglan Zhou,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[25]  R. Rowntree,et al.  The Phenotypic Consequences of CFTR Mutations , 2003, Annals of human genetics.

[26]  R. Boucher,et al.  Evidence for airway surface dehydration as the initiating event in CF airway disease , 2007, Journal of internal medicine.

[27]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[28]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.